Share: Facebook Twitter LinkedIn
Activity Provided By:

Paradigm Medical Communications, LLC.

Targeting Inflammatory and Fibrotic Pathways in SSc-ILD

Access Activity

Overview / Abstract:

Target Audience
This activity has been designed to address the educational needs of academic and community-based pulmonologists and rheumatologists. It may also benefit pathologists, radiologists, dermatologists, primary care physicians, nurse practitioners, PAs, pharmacists, nurses, residents, fellows, and other healthcare professionals involved in the care of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Statement of Need
Scleroderma or systemic sclerosis (SSc) is a rare autoimmune disorder characterized by fibrosis in the skin and internal organs, including the lungs, that results in increased morbidity and mortality for patients. SSc-ILD occurs in the majority of patients. Due to the rarity of the disease and the heterogeneity of symptoms, patients often experience diagnostic delay until referral to an appropriate specialist, thus delaying the opportunity for early treatment. For patients with risk factors for severe interstitial lung disease (ILD), rapid progression often occurs within the first 5 years from diagnosis. There is no curative treatment for SSc, but immunosuppressive agents and now antifibrotics are available to delay the progression of SSc-ILD. Patients with SSc need appropriate screening and monitoring for ILD. Patients presenting with ILD need appropriate screening for SSc, so that appropriate therapy can be initiated. Data are emerging for additional anti-inflammatory therapies that impact fibrosis, including tocilizumab and rituximab, as well as pirfenidone, an antifibrotic with efficacy in other forms of ILD. In this webinar diagnosis of SSc-ILD is reviewed for patients presenting with SSc and those presenting with ILD. Data for immunotherapies and antifibrotics are discussed, along with selecting therapy based on individual patient characteristics and risk factors for disease progression.

Learning Objectives
Upon completion of this activity, participants should be able to:
• Outline risk factors for progressive SSc-ILD
• Assess recommended monitoring for patients with scleroderma and SSc-ILD
• Select appropriate, evidence-based therapy for patients who have SSc-ILD

Expiration

Jul 09, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.25 AMA PRA Category 1 Credit™.

Presenters / Authors / Faculty

Fernando Jose Martinez, MD, MS
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb Company; DevPro Biopharma LLC; Sanofi-aventis U.S. LLC; Shionogi Inc.; United Therapeutics Corporation; Veracyte, Inc.
Grant/Research Support: Afferent Pharmaceuticals/Merck & Co, Inc; Bayer Corporation; Biogen-Idec; Respivant Sciences Company; Roche

Elizabeth R. Volkmann, MD, MS
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc
Grant/Research Support: Corbus Pharmaceuticals Holdings, Inc; Forbius; Bristol Myers Squibb Company; Kadmon Holdings, Inc

Sponsors / Supporters / Grant Providers

Genentech, a member of the Roche Group.

Keywords / Search Terms

Relias LLC Relias LLC Relias LLC., FREE CME., Fibrotic Pathways in SSc-ILD CE CME, Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map